[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)].

Abstract

Two patients were diagnosed as advanced breast cancer with multiple bone metastases. DMpC therapy (oral chemoendocrine combination therapy with doxifluridine, medroxyprogesterone acetate and cyclophosphamide) was chosen as first-line chemotherapy. After one month of the treatment, reductions in the primary tumors, lymph node metastases and metastatic bone lesions were noted. Only grade 2 leukopenia was observed as an adverse event in only one patient. DMpC therapy is an effective, easy and safe oral therapy. Therefore, it is possible to continue medication on an ambulatory basis for the long-term. DMpC therapy could thus be one the most useful treatments for advanced breast cancer.

• Authors: Minoru Kihara, Keiichi Kontani, Akira Yamauchi, Hiroyasu Yokomise
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 32 Issue 5 Pg. 683-6 (May 2005) ISSN: 0385-0684 [Print] Japan
• PMID: 15918573 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Floxuridine
• Cyclophosphamide
• Medroxyprogesterone Acetate
• doxifluridine

Topics

• Administration, Oral
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bone Neoplasms (secondary)
• Breast Neoplasms (drug therapy, pathology)
• Carcinoma, Ductal, Breast (drug therapy, secondary)
• Cyclophosphamide (administration & dosage)
• Drug Administration Schedule
• Female
• Floxuridine (administration & dosage)
• Humans
• Leukopenia (chemically induced)
• Lymph Nodes (pathology)
• Lymphatic Metastasis
• Medroxyprogesterone Acetate (administration & dosage)
• Middle Aged